CGEM

Cullinan Therapeutics (CGEM)

About Cullinan Therapeutics (CGEM)

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

Details

Daily high

$12.53

Daily low

$11.86

Price at open

$12.09

52 Week High

$13.43

52 Week Low

$5.68

Market cap

700.1M

Dividend yield

0.00%

Volume

420,196

Avg. volume

678,829

P/E ratio

-3.22

Cullinan Therapeutics News